CRISPR Therapeutics AG
NASDAQ:CRSP

Watchlist Manager
CRISPR Therapeutics AG Logo
CRISPR Therapeutics AG
NASDAQ:CRSP
Watchlist
Price: 54.74 USD -2.2% Market Closed
Market Cap: 5.2B USD

Wall Street
Price Targets

CRSP Price Targets Summary
CRISPR Therapeutics AG

Wall Street analysts forecast CRSP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CRSP is 80 USD with a low forecast of 32.32 USD and a high forecast of 281.4 USD.

Lowest
Price Target
32.32 USD
41% Downside
Average
Price Target
80 USD
46% Upside
Highest
Price Target
281.4 USD
414% Upside
CRISPR Therapeutics AG Competitors:
Price Targets
SOBI
Swedish Orphan Biovitrum AB (publ)
11% Upside
ADAG
Adagene Inc
406% Upside
CHRS
Coherus BioSciences Inc
278% Upside
688192
Dizal Jiangsu Pharmaceutical Co Ltd
68% Upside
BSLN
Basilea Pharmaceutica AG
52% Upside
VYGR
Voyager Therapeutics Inc
259% Upside
XGN
Exagen Inc
146% Upside

Revenue
Forecast

Revenue Estimate
CRISPR Therapeutics AG

For the last 9 years the compound annual growth rate for CRISPR Therapeutics AG's revenue is 79%. The projected CAGR for the next 4 years is 118%.

79%
Past Growth
118%
Estimated Growth
Estimates Accuracy
13%
Average Beat

Operating Income
Forecast

Operating Income Estimate
CRISPR Therapeutics AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Net Income
Forecast

Net Income Estimate
CRISPR Therapeutics AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-38%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CRSP's stock price target?
Price Target
80 USD

According to Wall Street analysts, the average 1-year price target for CRSP is 80 USD with a low forecast of 32.32 USD and a high forecast of 281.4 USD.

What is CRISPR Therapeutics AG's Revenue forecast?
Projected CAGR
118%

For the last 9 years the compound annual growth rate for CRISPR Therapeutics AG's revenue is 79%. The projected CAGR for the next 4 years is 118%.

Back to Top